27.09.2018 • NewsElaine BurridgePerstorp

Perstorp Switches Investors, Gains Funds

Perstorp Switches Investors, Gains Funds (c) Perstorp
Perstorp Switches Investors, Gains Funds (c) Perstorp

French private equity group PAI Europe has transferred Swedish specialty chemicals company Perstorp from its IV fund to a new fund managed by PAI Partners with US-based Landmark Partners as lead investor along with other co-investors. Financial terms were not revealed.

In addition to the transfer, Landmark Partners and its co-investors have committed to invest around €130 million in Perstorp to fund its future growth.

Jan Secher, Perstorp’s president and CEO, commented: “We are delighted that our focus on commercial and operational excellence has delivered strong results, attracting new quality investors. We have progressively enhanced profitability and deleveraging, resulting in the recent upgrade by S&P, and we are now ready to take the next step. We look forward to capturing future growth opportunities to advance our position as a global leader in specialty chemicals.”

S&P upgraded  its credit rating  for Perstorp in July to reflect the company’s sustained  EBITDA growth and deleveraging, citing the strong rise in volumes seen in the Swedish group’s main business lines over the past several quarters. Magnus Heimburg, Perstorp’s chief financial officer, said the upgrade should further increase its financial flexibility and potentially lower its future cost of capital.

Perstorp employs 1,500 people across production plants in Europe, North America and Asia. In 2017, it posted a record EBITDA of 2.1 billion krona on sales of 13.6 billion krona.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.